# Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19

> **NCT06197217** · PHASE3 · COMPLETED · sponsor: **Westlake Pharmaceuticals (Hangzhou) Co., Ltd.** · enrollment: 1350 (actual)

## Conditions studied

- Mild to Moderate COVID-19

## Interventions

- **DRUG:** WPV01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06197217
- **Lead sponsor:** Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-14
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-09-20
- **Target enrollment:** 1350 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06197217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06197217, "Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06197217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*